QLS31901 / Qilu Pharma - LARVOL DELTA

QLS31901, a novel bifunctional anti-PD-L1/TGF-β fusion protein for treatment of solid tumors (AACR 2022) - "While the antitumor activity of bifunctional anti-PD-L1/transforming growth factor-β (TGF-β) fusion protein bintrafusp alfa (M7824) in preclinical studies is well known, clinical studies to date with M7824 have led to limited success. There were no other cytokine release and organ toxicity in cynomolgus monkeys. Overall, these data provided a rationale for an expansion cohort study of QLS31901 for the treatment of patients with solid tumors and dual blockade of TGF-β as well as PD-L1 with QLS31901 may be a promising therapy."

Oncology • Solid Tumor • IL6 • TGFB1

A Study of Bispecific Antibody QLS31901 in Patients With Advanced orMetastatic Malignancies (clinicaltrials.gov) - P1; N=96; Recruiting; Sponsor: Qilu Pharmaceutical Co., Ltd.

Clinical • New P1 trial • Oncology